Akido's $60 Million Leap: Revolutionizing Healthcare with AI
May 17, 2025, 3:33 am
Location: United States, California, Los Angeles
Employees: 201-500
Founded date: 2015
Total raised: $96.2M
In a world where healthcare often feels like a maze, Akido Labs Inc. is charting a new course. The Los Angeles-based company recently secured $60 million in Series B funding, a significant boost aimed at expanding its innovative AI platform, ScopeAI. This funding round was led by Oak HC/FT, with participation from notable investors like Y Combinator and Google DeepMind's Jeff Dean.
Founded in 2015, Akido is on a mission to transform healthcare delivery, especially for underserved populations. The company’s vision is clear: harness artificial intelligence to bridge the gap between patients and quality care. In a landscape marked by physician shortages and rising demand, Akido’s approach is both timely and necessary.
At the heart of Akido’s strategy is ScopeAI, an AI-driven clinical co-pilot designed to streamline patient visits. Imagine a tool that not only assists medical professionals but also learns and evolves. ScopeAI dynamically generates relevant clinical questions, captures patient responses in real time, and drafts documentation. This reduces the administrative burden on healthcare providers, allowing them to focus on what truly matters: patient care.
ScopeAI operates on a reinforcement-learning model. Think of it as a student in a classroom, absorbing lessons and improving with each test. This ongoing training loop refines the model’s accuracy, ensuring it adapts to the nuances of clinical practice. The result? Faster, safer decision-making across diverse patient populations.
The implications of this technology are profound. By automating large portions of the intake and documentation process, ScopeAI enables healthcare providers to see more patients without sacrificing quality. This is particularly crucial in high-demand settings like street medicine programs and public clinics, where every minute counts.
Akido’s co-founder and CEO, Prashant Samant, emphasizes the urgency of their mission. The global healthcare system is grappling with a physician shortage, a challenge that only seems to grow. Akido aims to empower healthcare providers, ensuring that patients receive timely, high-quality care, regardless of their financial means or geographic location.
The funding will also support the expansion of Akido Care, a medical network that currently includes nearly 100 clinics across 26 specialties. This network is a testament to Akido’s commitment to delivering comprehensive care. By integrating AI with empathy, Akido is redefining the patient experience.
The recent investment reflects a growing recognition of the potential of AI in healthcare. Investors see Akido as a pioneer, one that is not just promising but delivering results. The company’s robust dataset and refined foundational model set it apart from competitors. It’s not just about technology; it’s about improving lives.
Healthcare is often viewed through a lens of complexity. But Akido simplifies this. By focusing on the intersection of AI and human care, the company is creating pathways to better health outcomes. It’s a delicate balance—technology must enhance, not replace, the human touch in medicine.
As Akido continues to grow, the spotlight will be on its ability to adapt and innovate. The healthcare landscape is ever-changing, and agility will be key. The company’s commitment to ongoing learning and improvement positions it well for the future.
In a world where healthcare can feel like a battleground, Akido is a beacon of hope. The $60 million funding is not just a financial boost; it’s a vote of confidence in a vision that prioritizes access and quality. With ScopeAI, Akido is not just addressing the symptoms of healthcare challenges; it’s tackling the root causes.
The journey ahead is filled with potential. As Akido expands its reach, it will undoubtedly face challenges. But with a strong foundation and a clear mission, the company is poised to make a lasting impact. The integration of AI in healthcare is not just a trend; it’s the future.
In conclusion, Akido Labs is more than a tech company. It’s a catalyst for change in the healthcare industry. The recent funding marks a pivotal moment, one that could reshape how care is delivered. As they continue to innovate, the hope is that more patients will experience the benefits of timely, high-quality care. In the end, it’s about people—patients and providers alike—and ensuring that everyone has access to the care they deserve.
Founded in 2015, Akido is on a mission to transform healthcare delivery, especially for underserved populations. The company’s vision is clear: harness artificial intelligence to bridge the gap between patients and quality care. In a landscape marked by physician shortages and rising demand, Akido’s approach is both timely and necessary.
At the heart of Akido’s strategy is ScopeAI, an AI-driven clinical co-pilot designed to streamline patient visits. Imagine a tool that not only assists medical professionals but also learns and evolves. ScopeAI dynamically generates relevant clinical questions, captures patient responses in real time, and drafts documentation. This reduces the administrative burden on healthcare providers, allowing them to focus on what truly matters: patient care.
ScopeAI operates on a reinforcement-learning model. Think of it as a student in a classroom, absorbing lessons and improving with each test. This ongoing training loop refines the model’s accuracy, ensuring it adapts to the nuances of clinical practice. The result? Faster, safer decision-making across diverse patient populations.
The implications of this technology are profound. By automating large portions of the intake and documentation process, ScopeAI enables healthcare providers to see more patients without sacrificing quality. This is particularly crucial in high-demand settings like street medicine programs and public clinics, where every minute counts.
Akido’s co-founder and CEO, Prashant Samant, emphasizes the urgency of their mission. The global healthcare system is grappling with a physician shortage, a challenge that only seems to grow. Akido aims to empower healthcare providers, ensuring that patients receive timely, high-quality care, regardless of their financial means or geographic location.
The funding will also support the expansion of Akido Care, a medical network that currently includes nearly 100 clinics across 26 specialties. This network is a testament to Akido’s commitment to delivering comprehensive care. By integrating AI with empathy, Akido is redefining the patient experience.
The recent investment reflects a growing recognition of the potential of AI in healthcare. Investors see Akido as a pioneer, one that is not just promising but delivering results. The company’s robust dataset and refined foundational model set it apart from competitors. It’s not just about technology; it’s about improving lives.
Healthcare is often viewed through a lens of complexity. But Akido simplifies this. By focusing on the intersection of AI and human care, the company is creating pathways to better health outcomes. It’s a delicate balance—technology must enhance, not replace, the human touch in medicine.
As Akido continues to grow, the spotlight will be on its ability to adapt and innovate. The healthcare landscape is ever-changing, and agility will be key. The company’s commitment to ongoing learning and improvement positions it well for the future.
In a world where healthcare can feel like a battleground, Akido is a beacon of hope. The $60 million funding is not just a financial boost; it’s a vote of confidence in a vision that prioritizes access and quality. With ScopeAI, Akido is not just addressing the symptoms of healthcare challenges; it’s tackling the root causes.
The journey ahead is filled with potential. As Akido expands its reach, it will undoubtedly face challenges. But with a strong foundation and a clear mission, the company is poised to make a lasting impact. The integration of AI in healthcare is not just a trend; it’s the future.
In conclusion, Akido Labs is more than a tech company. It’s a catalyst for change in the healthcare industry. The recent funding marks a pivotal moment, one that could reshape how care is delivered. As they continue to innovate, the hope is that more patients will experience the benefits of timely, high-quality care. In the end, it’s about people—patients and providers alike—and ensuring that everyone has access to the care they deserve.